PRGN-3008
/ Precigen
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 10, 2025
Increased Potency, Persistence, and Stem Cell Memory/Naïve Phenotype is Achieved with PRGN-3008 UltraCAR-T, an Overnight-Manufactured CD19 CAR-T Cell Expressing membrane-bound IL-15 and miRNA-based PD-1 Blockade from a Single Non-Viral Transposon
(ASGCT 2025)
- "These results demonstrate that the PRGN-3008 has potential to be the best-in-class treatment. Disease Focus of Abstract:Cancer Hematologic"
CAR T-Cell Therapy • IO biomarker • Hematological Malignancies • Oncology • CD19 • IL15
November 14, 2024
Precigen Reports Third Quarter 2024 Financial Results and Business Updates
(PRNewswire)
- "Preclinical data for PRGN-3008 were presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting in a poster presentation....Preclinical data showed that in in vivo tumor models, a single administration of PRGN-3008 enhanced expansion and persistence, produced robust antitumor efficacy with complete tumor clearance, and demonstrated significantly longer survival compared to conventional CD19 CAR-T cells. In a simulation of tumor relapse in the in vivo model, PRGN-3008 demonstrated persistence and long-term antitumor immunity extending overall survival without additional PRGN-3008 treatment."
Preclinical • Oncology
1 to 2
Of
2
Go to page
1